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Supplemental Figures
Figure S1. Production rhGNS using pCI-neo vector. A) rhGNS expression plasmid. B) rhGNS high 
expression clone selection. C-D) Monitor of rhGNS secretion via GNS activity (C) and SDS-PAGE (D).
Figure S2. A) Identification of rhGNS using antibodies against GNS and myc. B) Native PAGE of 
rhGNS. Purified rhGNS was resolved in a non-denaturing Tris/Bis gel by electrophoresis, exhibiting an 
estimated molecular weight of 160-200 kDa, suggesting that it forms either a homodimer or trimer 
conformation. C) pH profile of rhGNS using the sulfatase assay. Both the commercially available and 
our own product demonstrated a pH optimum of approximately 5.6 against the substrate PNCS with 
overlapping pH profiles
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Figure S3. Production and characterization of rhGNS using popvec vector. A) rhGNS expression 
plasmid TCB616. B) rhGNS high expression clone selection. C) Monitor of rhGNS secretion via GNS 
activity. D) Quantified the percentage of rhGNS in total secreted proteins via western blot. E) The purity 
of purified rhGNS detected by size exclusion chromatography. F) The inflection temperature of rhGNS 
is 83.7°C. G) Michaelis-Menten kinetics curve of rhGNS purified from TCB616 C2. The calculated Km 
was 6.0 ± 1.2 mM, and the estimated kcat was determined to be 3.0*10^4 units/mg. H) Sulfatase activity 
detected the pH profile of rhGNS. I) Sulfatase activity detected the temperature profile of purified rhGNS 
and the commercial R&D GNS. J) SDS-PAGE of purified rhGNS treated by glycosidase PNGase F.
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(nmol/hr/mg) Fold-enrichment % Yield
Before 725 118 3993.8 33.7 1 　
Conc. 100 114 25943 226.6 6.7 100%
Unbound 100 113 11669 94.8 2.8 45%
Elution 0.2 0.16 2086 13400 397.4 8%
Note: 1 unit = 1 nmol converted substrate per h at 37 ˚C. The substrate is 4-methylumbelliferyl N-acetyl-
glucosamine-6-sulfate.
S-5
Table S4. LC/MS/MS analysis of trypsin digested rhGNS further confirmed the identity of rhGNS 













5.48E10 100 49.64 552 62.1
Histone H4 
OS=Homo sapiens  
2.12E9 4 51.46 103 11.4
Isoform 3 of T-
complex protein 1 
subunit eta 
2.80E9 5 30.06 499 54.8
Note: analysis of rhGNS from myc affinity purification by LC/MS/MS analysis determined two major contaminant 
proteins are Histone H4 and Isoform 3 of T-complex protein 1 subunit eta (CCT7).
Table S5. Quantification the purity of rhGNS purified from TCB469 B2 using ImageJ.
Total area 80 kDa band Purity (%)
2.5 g 1.33E+05 5.13E+04 38.4
1.33E+05 5.59E+04 41.9
5 g 1.64E+05 8.92E+04 54.2
1.64E+05 9.77E+04 59.4
Average 48.5












Before 800 93 611438 6570 1 　 　
Conc. 40 78 552750 7045 1.1 100%
Load 10 21 146906 7045 1.1 27% 100%
Unbound 12 13 83529 6202 0.9 15% 62%
Elution 4 3 2086 38989 5.9 3.8%* 14.3%*
*Yield of 3.8% is calculated from 78 mg of total protein: we only took 21 mg to load onto the myc-
agarose due to its binding capacity. The normalized yield to 21 mg is 14.3%.
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Table S7. LC/MS/MS analysis of trypsin digested rhGNS further confirmed the identity of rhGNS 
purified from TCB616 C2.
Description Abundance






N-acetylglucosamine-6-sulfatase OS=Homo sapiens OX=9606 
GN=GNS PE=1 SV=3
6.90E+09 100.000 62.00 8.31
Endoplasmic reticulum chaperone BiP OS=Cricetulus griseus 
OX=10029 GN=HSPA5 PE=1 SV=1
2.18E+07 0.316 72.30 5.16
Transducin-like enhancer protein 1 OS=Homo sapiens OX=9606 
GN=TLE1 PE=1 SV=2
1.68E+07 0.243 83.10 7.24
Galectin-3-binding protein OS=Cricetulus griseus OX=10029 
GN=CgPICR_011982 PE=4 SV=1
1.60E+07 0.233 63.8 5.19
Histone H4 OS=Cricetulus griseus OX=10029 GN=I79_012827 
PE=3 SV=1
4.95E+06 0.072 28.4 11.03
N-acetylglucosamine-6-sulfatase OS=Cricetulus griseus 
OX=10029 GN=I79_019923 PE=3 SV=1
3.84E+06 0.056 53.7 6.87
Peptidyl-prolyl cis-trans isomerase OS=Cricetulus griseus 
OX=10029 GN=CgPICR_005246 PE=3 SV=1
3.06E+06 0.044 23.6 9.58
Cation-independent mannose-6-phosphate receptor 
OS=Cricetulus griseus OX=10029 GN=I79_009791 PE=4 SV=1
2.26E+06 0.033 186.5 5.41
Ubiquinone biosynthesis O-methyltransferase, mitochondrial 
OS=Homo sapiens OX=9606 GN=COQ3 PE=1 SV=3
2.15E+06 0.031 41 7.42
Histone H3.1t OS=Cricetulus griseus OX=10029 
GN=I79_010126 PE=3 SV=1
1.99E+06 0.029 35.8 10.71
Annexin OS=Cricetulus griseus OX=10029 GN=I79_018648 
PE=3 SV=1
1.66E+06 0.024 36 5.05
(Common contaminant protein) 1.62E+06 0.023 24.4 7.18
LGMN OS=Cricetulus griseus OX=10029 GN=CgPICR_012975 
PE=1 SV=1
1.46E+06 0.021 49.6 6.55
Ferritin OS=Cricetulus griseus OX=10029 GN=CgPICR_006768 
PE=3 SV=1
1.32E+06 0.019 21.5 6.16
Dermatopontin OS=Cricetulus griseus OX=10029 
GN=I79_008827 PE=4 SV=1
1.09E+06 0.016 24 4.89
Histone H4 OS=Cricetulus griseus OX=10029 GN=I79_012828 
PE=3 SV=1
1.09E+06 0.016 21.8 10.7
Annexin A2 OS=Homo sapiens OX=9606 GN=ANXA2 PE=1 
SV=2
1.06E+06 0.015 38.6 7.75
Cathepsin B OS=Cricetulus griseus OX=10029 GN=I79_003681 
PE=3 SV=1
1.05E+06 0.015 37.5 6.13
ATP-binding cassette sub-family A member 9 OS=Homo sapiens 
OX=9606 GN=ABCA9 PE=1 SV=1
1.02E+06 0.015 184.2 6.93
Protein disulfide-isomerase A4 OS=Cricetulus griseus OX=10029 
GN=CgPICR_019838 PE=3 SV=1
8.81E+05 0.013 72.5 5.17
Protein disulfide-isomerase OS=Homo sapiens OX=9606 
GN=P4HB PE=1 SV=3
8.64E+05 0.013 57.1 4.87
Metalloproteinase inhibitor 2 OS=Cricetulus griseus OX=10029 
GN=I79_004761 PE=4 SV=1
8.38E+05 0.012 21.5 7.52
Peroxiredoxin-1 OS=Cricetulus griseus OX=10029 
GN=I79_002954 PE=4 SV=1
8.03E+05 0.012 22.2 7.72
CTSZ OS=Cricetulus griseus OX=10029 GN=ctsz PE=2 SV=1 7.90E+05 0.011 34 7.58
Cathepsin L1 OS=Cricetulus griseus OX=10029 GN=I79_025440 
PE=3 SV=1
7.15E+05 0.010 37.2 7.17
Galectin OS=Cricetulus griseus OX=10029 GN=I79_006244 
PE=4 SV=1
6.16E+05 0.009 32.4 7.37
Procollagen C-endopeptidase enhancer 1 OS=Cricetulus griseus 
OX=10029 GN=H671_4g12064 PE=4 SV=1
5.81E+05 0.008 55.2 8.13
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Peroxiredoxin-4 (Fragment) OS=Homo sapiens OX=9606 
GN=PRDX4 PE=1 SV=1
4.90E+05 0.007 18.3 6.19
Carboxypeptidase OS=Cricetulus griseus OX=10029 
GN=I79_006816 PE=3 SV=1
4.78E+05 0.007 54.2 6.11
Ribonuclease T2 OS=Cricetulus griseus OX=10029 
GN=I79_018311 PE=3 SV=1
4.75E+05 0.007 29.5 6.73
Cation-independent mannose-6-phosphate receptor OS=Homo 
sapiens OX=9606 GN=IGF2R PE=1 SV=3
4.62E+05 0.007 274.2 5.94
Lysosomal Pro-X carboxypeptidase OS=Cricetulus griseus 
OX=10029 GN=CgPICR_008653 PE=4 SV=1
4.53E+05 0.007 55.4 6.65
Protein S100 OS=Cricetulus griseus OX=10029 
GN=CgPICR_013596 PE=3 SV=1
4.50E+05 0.007 10 5.48
Calmodulin OS=Cricetulus griseus OX=10029 GN=I79_024941 
PE=3 SV=1
4.09E+05 0.006 16.7 4.39
Amyloid-beta precursor protein (Fragment) OS=Homo sapiens 
OX=9606 GN=APP PE=1 SV=1
4.01E+05 0.006 55.1 4.82
Nidogen-1 OS=Cricetulus griseus OX=10029 GN=I79_015301 
PE=4 SV=1
3.92E+05 0.006 79 4.88
Alpha-galactosidase OS=Cricetulus griseus OX=10029 
GN=I79_016839 PE=3 SV=1
3.81E+05 0.006 47.2 7.84
N-acetylglucosamine-6-sulfatase (Fragment) OS=Homo sapiens 
OX=9606 GN=GNS PE=1 SV=8
3.76E+05 0.005 28.3 8.9
Transaldolase OS=Cricetulus griseus OX=10029 
GN=H671_3g9883 PE=3 SV=1
3.65E+05 0.005 37.5 7.03
SPARC OS=Homo sapiens OX=9606 GN=SPARC PE=1 SV=1 3.43E+05 0.005 34.6 4.84
Protein disulfide-isomerase A3 OS=Homo sapiens OX=9606 
GN=PDIA3 PE=1 SV=4
3.20E+05 0.005 56.7 6.35
Annexin OS=Cricetulus griseus OX=10029 GN=H671_3g10393 
PE=3 SV=1
3.19E+05 0.005 38.8 7.02
Beta-hexosaminidase OS=Cricetulus griseus OX=10029 
GN=I79_015800 PE=3 SV=1
3.08E+05 0.004 60.1 7.36
Tubulointerstitial nephritis antigen-like OS=Cricetulus griseus 
OX=10029 GN=I79_004150 PE=3 SV=1
2.99E+05 0.004 52.5 7.08
Glutathione S-transferase P OS=Cricetulus griseus OX=10029 
GN=I79_018157 PE=4 SV=1
2.94E+05 0.004 25 8.12
Deoxyribonuclease-2-alpha OS=Cricetulus griseus OX=10029 
GN=H671_3g9963 PE=4 SV=1
2.70E+05 0.004 40.4 7.55
Protein disulfide-isomerase A6 OS=Cricetulus griseus OX=10029 
GN=I79_007616 PE=4 SV=1
2.23E+05 0.003 28.4 4.91
Calcium-dependent serine proteinase OS=Cricetulus griseus 
OX=10029 GN=I79_001431 PE=3 SV=1
2.17E+05 0.003 77.4 4.82
Aspartate aminotransferase OS=Cricetulus griseus OX=10029 
GN=CgPICR_007832 PE=4 SV=1
2.11E+05 0.003 46.2 7.21
Basement membrane-specific heparan sulfate proteoglycan core 
protein OS=Cricetulus griseus OX=10029 GN=I79_010495 PE=4 
SV=1
2.10E+05 0.003 333.9 6.87
Laminin subunit gamma-1 OS=Cricetulus griseus OX=10029 
GN=I79_009544 PE=4 SV=1
2.01E+05 0.003 172 5.07
EZR OS=Cricetulus griseus OX=10029 GN=CgPICR_011481 
PE=4 SV=1
2.01E+05 0.003 69.3 6.37
Metalloproteinase inhibitor 1 OS=Cricetulus griseus OX=10029 
GN=CgPICR_020423 PE=4 SV=1
1.96E+05 0.003 22.4 8.47
AGA OS=Cricetulus griseus OX=10029 GN=CgPICR_008921 
PE=4 SV=1
1.77E+05 0.003 37.2 7.46
Calreticulin OS=Cricetulus griseus OX=10029 
GN=CgPICR_020604 PE=3 SV=1
1.73E+05 0.003 48.2 4.49
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Nucleolin OS=Cricetulus griseus OX=10029 GN=I79_022400 
PE=4 SV=1
1.59E+05 0.002 52.4 4.5
Collagen alpha-1(III) chain OS=Cricetulus griseus OX=10029 
GN=I79_024950 PE=4 SV=1
1.46E+05 0.002 114.9 4.94
Alpha-actinin-4 OS=Homo sapiens OX=9606 GN=ACTN4 PE=1 
SV=2
1.38E+05 0.002 59.5 4.94
Sulfated glycoprotein 1 OS=Cricetulus griseus OX=10029 
GN=I79_017410 PE=4 SV=1
1.27E+05 0.002 27.4 5.49
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 
OS=Cricetulus griseus OX=10029 GN=I79_023615 PE=4 SV=1
1.25E+05 0.002 75.9 6.2
Peptidyl-prolyl cis-trans isomerase-like 1 OS=Homo sapiens 
OX=9606 GN=PPIL1 PE=1 SV=1
1.20E+05 0.002 18.2 7.99
Cathepsin D OS=Cricetulus griseus OX=10029 
GN=H671_3g9701 PE=3 SV=1
1.18E+05 0.002 44.1 6.98
Glutathione synthetase OS=Cricetulus griseus OX=10029 
GN=I79_007504 PE=3 SV=1
1.10E+05 0.002 52.2 5.57
Leukocyte elastase inhibitor A OS=Cricetulus griseus OX=10029 
GN=CgPICR_009798 PE=3 SV=1
1.09E+05 0.002 42.9 6.16
Vimentin OS=Homo sapiens OX=9606 GN=VIM PE=1 SV=4 1.06E+05 0.002 53.6 5.12
Activated RNA polymerase II transcriptional coactivator p15 
OS=Homo sapiens OX=9606 GN=SUB1 PE=1 SV=3
1.05E+05 0.002 14.4 9.6
Collagen alpha-1(V) chain OS=Homo sapiens OX=9606 
GN=COL5A1 PE=1 SV=3
1.03E+05 0.001 183.4 5.06
Prelamin-A/C OS=Homo sapiens OX=9606 GN=LMNA PE=1 
SV=1
1.01E+05 0.001 74.1 7.02
ARHGDIA OS=Cricetulus griseus OX=10029 
GN=CgPICR_011939 PE=4 SV=1
1.01E+05 0.001 23.4 5.2
Golgi apparatus protein 1 OS=Homo sapiens OX=9606 
GN=GLG1 PE=1 SV=2
9.96E+04 0.001 134.5 6.9
Heat shock protein HSP 90-alpha OS=Homo sapiens OX=9606 
GN=HSP90AA1 PE=1 SV=5
9.60E+04 0.001 84.6 5.02
Mpv17-like protein 2 OS=Cricetulus griseus OX=10029 
GN=I79_005109 PE=4 SV=1
8.85E+04 0.001 52.4 8.24
Acid ceramidase OS=Cricetulus griseus OX=10029 
GN=I79_003173 PE=3 SV=1
8.07E+04 0.001 44.7 7.9
Heat shock cognate 71 kDa protein OS=Homo sapiens OX=9606 
GN=HSPA8 PE=1 SV=1
7.64E+04 0.001 68.8 5.52
Collagen alpha-2(V) chain OS=Cricetulus griseus OX=10029 
GN=I79_024376 PE=4 SV=1
7.48E+04 0.001 19 7.72
Nucleophosmin OS=Cricetulus griseus OX=10029 
GN=I79_020971 PE=4 SV=1
7.01E+04 0.001 31 4.67
Neuroplastin OS=Homo sapiens OX=9606 GN=NPTN PE=1 
SV=2
6.65E+04 0.001 44.4 7.99
ARSA OS=Cricetulus griseus OX=10029 GN=CgPICR_000077 
PE=4 SV=1
6.38E+04 0.001 55 5.15
Nucleoside diphosphate kinase A OS=Homo sapiens OX=9606 
GN=NME1 PE=1 SV=1
6.29E+04 0.001 17.1 6.19
Di-N-acetylchitobiase OS=Cricetulus griseus OX=10029 
GN=I79_011948 PE=3 SV=1
6.19E+04 0.001 32.9 5.67
Matrix metalloproteinase-9 OS=Cricetulus griseus OX=10029 
GN=I79_006812 PE=3 SV=1
5.65E+04 0.001 78.8 5.94
Lactotransferrin (Fragment) OS=Homo sapiens OX=9606 
GN=LTF PE=1 SV=1
5.55E+04 0.001 76.6 8.02
Chondroitin sulfate proteoglycan 4 OS=Cricetulus griseus 
OX=10029 GN=I79_003599 PE=4 SV=1
5.05E+04 0.001 251.9 5.68
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Neogenin OS=Cricetulus griseus OX=10029 GN=I79_008978 
PE=4 SV=1
4.94E+04 0.001 154.4 6.64
Serine/threonine-protein kinase DCLK2 OS=Cricetulus griseus 
OX=10029 GN=I79_011199 PE=4 SV=1
4.68E+04 0.001 108.3 6.81
Transaldolase OS=Cricetulus griseus OX=10029 
GN=I79_024784 PE=3 SV=1
4.39E+04 0.001 36.1 5.24
Pantetheinase OS=Cricetulus griseus OX=10029 
GN=I79_019325 PE=4 SV=1
4.32E+04 0.001 56.7 5.63
Protein S100 OS=Cricetulus griseus OX=10029 
GN=H671_1g3381 PE=3 SV=1
4.24E+04 0.001 11.2 7.08
N-sulphoglucosamine sulphohydrolase OS=Cricetulus griseus 
OX=10029 GN=CgPICR_011967 PE=4 SV=1
4.21E+04 0.001 56.5 6.52
Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 
OS=Homo sapiens OX=9606 GN=DUT PE=1 SV=1
3.67E+04 0.001 15.4 6.57
Note: analysis of rhGNS from myc affinity purification from TCB616 C2 by LC/MS/MS analysis determined no 
major contaminant proteins from CHO cells.
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Supplemental Methods
1. Assay Optimization GNS Assay
While the Sulfatase Assay provided a direct measurement of sulfatase activity, it is worth noting that 
para-nitrocatechol sulfate (PNCS) is a common substrate of several sulfatases and therefore lacks 
substrate specificity. To address this, we utilized a coupled, fluorometric assay using 4-MU-GNS, which 
has been used previously and more closely mimics the natural substrate of the GNS enzyme, which 
we term the “GNS Assay”. The GNS activity assay was completed in two parts, where the first step 
involved incubation with 4-MUGNS, producing 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-D-
glucopyranoside, and the second step involved addition of alpha-N-acetylglucosaminidase (NAGLU) to 
release 4-MU, which exhibits an excitation/emission profile of 360/450nm. The GNS assay was first 
developed over twenty years ago primarily for the diagnosis of MPSIIID patients; therefore the assay 
was carried out over a prolonged 24-48 hour incubation period due to the low concentration of the 
enzyme present in cell lysates of healthy individuals.
Because the assay requires two sequential reaction steps, it was essential that the second step 
enzyme was not limiting for the amount of product produced from the first (GNS) reaction. Therefore, 
highly concentrated stocks of recombinant human NAGLU conditioned media were produced. We then 
used this concentrated media for optimization and found that using 5 µL of the 20 x concentrated 
rhNAGLU stock after 30 minutes we were able to achieve complete turnover of 4-methylumbelliferyl-2-
acetamido-2-deoxy-alpha-D-glucopyranoside produced by 20 ng of rhGNS after one hour reaction time 
(>250 nmol 4-MU).
2. Sulfatase Assay
An absorbance-based measurement of GNS sulfatase activity was adapted from the protocol provided 
by R&D systems with modifications using a 96-well plate format. Each well containing 10 µL of 2 µg/mL 
rhGNS in reaction buffer 1 (200 mM sodium acetate, pH 5.6, 0.01% Triton X-100) was incubated with 
40 µL of 2.5 mM para-nitrocatechol sulfate (PNCS) for 1-4 hours at 37 °C. Following incubation, 50 µL 
of 0.2 M NaOH was added to stop reactions, and plates were then centrifuged at 1000 rpm for 1 min. 
Absorbance was measured at 510 nm using the Synergy Neo 2 Multi-Mode microplate reader (BioTek). 
Each reaction condition was carried out in triplicate.
3. Assay Optimization Sulfatase Assay
Two assays were used to assess GNS activity, the first of which is a colorimetric assay utilized para-
nitrocatechol-sulfate (PNCS), an artificial substrate of non-specific sulfatase activity. Cleavage of the 
sulfate group occurs in a one-step reaction producing para-nitrocatechol (PNC), yielding maximum 
absorbance at 510 nm under basic conditions and referred to as the “Sulfatase Assay”. Individual buffer 
components were optimized in independent experiments. Enzyme activity remained relatively stable up 
to levels of 250 mM NaCl, whereas acetate concentration showed very minor effects. Experiments with 
other common biological buffers demonstrated that the enzyme is completely inhibited in the presence 
of free phosphate, sulfate, or citrate groups. Therefore, purification and other assay buffer conditions 
were similarly optimized to avoid addition of these components. Addition of the detergent Triton X-100 
(Sigma) significantly increased reproducibility and showed maximal enzyme specific activity at low 
concentrations (0.01%). In order to test activity over a range of pH, we use three buffer conditions to 
cover the range of pH values: acetate (pKa=4.76; range=3.2-5.6), MES (pKa=6.16; range=5.5-6.7), and 
HEPES (pKa=7.55; range=6.8-8.2).
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4. SDS-PAGE and Western Blotting
Samples were loaded on a 4-20% Tris-Glycine Mini-PROTEAN Gels (Bio-Rad) along with 
KaleidoscopeTM protein standard (Bio-Rad) as a molecular weight marker. Protein bands were 
visualized by staining with ImperialTM protein stain (Thermo Scientific, Waltham, MA) or transferred onto 
nitrocellulose membranes using the Trans-Blot Turbo system (Bio-Rad) for western blotting. After 
blocking with 5% milk in TBST (20 mM Tris, 150 mM NaCl, 0.1% (w/v) Tween-20), membranes were 
probed with either goat anti-GNS antibody (R&D Systems, AF2484), mouse anti-c-myc antibody 
(Thermo Scientific, Waltham, MA1-21316), mouse anti-LAMP1 (DSHB, 1D4B), or rabbit anti-GAPDH 
(CST, Cat # 2118) overnight at 4 °C. After washing, membranes were incubated for 2 hours at room 
temperature with HRP-conjugated secondary antibodies. ECL reagent (WBKLS0500, MilliporeSigma) 
and ChemiDoc MP Imaging System (Bio-Rad) were used to image the blots. Gel bands quantification 
was performed using Image J.
5. Native Polyacrylamide Gel Electrophoresis
Native polyacrylamide gel electrophoresis was performed using Novex Tris-Glycine Gels (Cat# 
XP00100BOX, Thermofisher). Purified rhGNS was mixed with Novex Tris-Glycine Native Sample Buffer 
(Cat# LC2673, Thermofisher), 0.5 µg protein was loaded into each lane. Run the gel at 225 V constant 
for 35 miuntes.
6. Thermal Shift Assay
Thermal shift assay was performed with Tycho (Nanotemper, Germany), utilizing intrinsic tryptophan 
fluorescence. Generally, purified rhGNS was diluted in artificial CSF to 10 µg/mL, then centrifuge for 30 
minutes at 13,000 g, 4 °C. Clean capillary (Tycho NT.6 Capillaries, Nanotemper) was filled with 
supernatant then loaded into capillary tray. Samples were heated from 35 °C to 95 °C in 3 minutes and 
inflection temperature was calculated by the software automatically.
7. Lysosome Purification
The lysosome fractions from brains harvested from MPS IIID mutant (GNS-/-) mice treated with or 
without rhGNS along with age-matched carrier control (GNS-/-) mice were enriched using the Lysosome 
Enrichment Kit for Tissue and Cultured Cells (Thermo Scientific, Waltham, MA) according to the 
manufacturer‘s instructions. Isolated lysosomes were lysed in GNS lysis buffer before enzyme activity 
assays and Westen blots.
8. LC/MS/MS
In solution tryptic digest followed by nano-liquid chromatography–tandem mass spectrometry analysis. 
Purified protein (100 μL) were diluted with 25 μL 100 mM Tris buffer (pH 8.5), reduced with 1 μL 0.5 M 
tris (2-carboxyethyl) phosphine hydrochloride (Thermo Fisher Scientific) for 20 min at 37 °C, alkylated 
with 3 μL 0.5 M chloroacetamide (Fisher) for 15 min at 37 °C, and digested with 2 μL 100 ng/μL Lysyl 
endopeptidase (Wako Chemicals; Lys-C) for 4 h at 37 °C. And then digested with 3 μL 100 ng/μL trypsin 
(Thermo Fisher Scientific) with 5 μL 100mM CaCl2 for 18 h at 37 °C. After desalting with Pierce C18 
Tip (Thermo Fisher Scientific), peptides were eluted with 200 μL 75% (vol/vol) acetonitrile (ACN) 0.1% 
TFA. Solvent was removed using a SpeedVac. 
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For rhGNS purified from TCB469 B2 (table S4), dried peptides were acidified by 0.2% formic acid 
and loaded onto an Easy Nano-LC Q-Exactive Orbitrap (Thermo Fisher Scientific). Peptides were 
loaded onto to a trap column [PepMap 100 C18, 3 μm, 75 μm Å x 2 cm, nanoViper (Thermo Fisher 
Scientific)] and separated with an Easy-Spray column [PepMap C18, 3 μm 100 Å, 75 μm Å x 15 cm 
(Thermo Fisher Scientific, ES800) with a 2–30% (vol/vol) gradient (A: 0.1% formic acid [FA] in water; 
B: 0.1% FA in 100% CAN)] at 300 nL/min for 60 min followed by 30% (vol/vol) B to 100% B for 5 min 
and incubated at 100%B for 10 min. The Q-Exactive acquisition method was created in data-dependent 
mode with one precursor scan in the Orbitrap, followed by fragmentation of the 15 most abundant 
peaks. Resolution of the precursor scan was set to 70,000, automatic gain control target 3e6, maximum 
injection time 100 ms, scanning from 350 to 2,000 m/z. The MS2 resolution was 17,500, the AGC target 
5e4, the isolation window was 2.0 m/z, the fixed first mass 100.0 m/z, the normalized collision energy 
was 25, the underfill ratio was 0.1%, the charge exclusion was unassigned 1, peptide match was 
preferred, the exclude isotope option was on, and the dynamic exclusion was 30.0 s. The peak list 
generating software used was Proteome Discoverer Software (Thermo Fisher Scientific). The outline 
of the method used in the spectrum selector mode of the Proteome Discoverer software were all set to 
default settings to generate tandem MS spectra. The precursor charge state (high/low), retention time, 
minimum peak count, and total intensity threshold value were all set to default settings. The maximum 
and minimum precursor mass settings were 5,000 and 350 Da, respectively. The Human Fasta file 
(canonical and isoform) was downloaded from UniProt (www.uniprot.org).
The Sequest HT search parameters included in this study were two missed cleavages allowed, 
fully tryptic peptides only, minimum peptide length of 6, maximum peptide length of 144, fixed 
modification of carbamidomethyl cysteine (+57.021 Da), dynamic modifications of oxidized methionine 
(+15.995Da), and N-terminal acetylation (+42.011Da). The precursor ion mass tolerance was 10 ppm 
and fragment mass tolerance was 0.05 Da. The input data maximum delta was Cn 0.05. The decoy 
database search was applied with strict false discovery rates (FDR) of 0.01 and relaxed FDR of 0.05, 
where the validation was based on q value.
For rhGNS purified from TCB616 C2, dried peptides were acidified by 0.2% formic acid and 
subjected to LC-MS/MS analysis on an EASY-nLC 1200 coupled to a Q Exactive HF Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a Nanospray Flex ion 
source.  Peptides were directly loaded onto an Aurora 25cm x 75µm ID, 1.6µm C18 column (Ion 
Opticks) heated to 50°C.  The peptides were separated at a flow rate of 350 nL/min with the following 
gradient: 2–6% Solvent B (2 min), 6-25% B (20.5 min), 25-40% B (7.5 min), 40-98% B (1 min), and held 
at 98% B (12 min).  Solvent A consisted of 97.8 % H2O, 2% ACN, and 0.2% formic acid and solvent B 
consisted of 19.8% H2O, 80 % ACN, and 0.2% formic acid.  Full scan resolution was set to 60,000 at 
m/z 200.  Full scan target was 3e6 with a maximum injection time of 15 ms.  Mass range was set to 
375−1500 m/z.  For data dependent MS2 scans the loop count was 12, minimum AGC target value was 
set at 4.5e3, intensity threshold was 1e5, and maximum injection time was 45 ms.  Isolation width was 
set at 1.2 m/z and a fixed first mass of 100 was used.  Normalized collision energy was set at 
28.  Peptide match was set to off and isotope exclusion was on.  MS2 scans were acquired in centroid 
mode at a resolution of 30,000. 
Raw data were searched in Proteome Discoverer 2.4 (Thermo Scientific) using the Byonic search 
algorithm (Protein Metrics) and a FASTA file containing all human and Chinese hamster Uniprot protein 
sequences as well as common contaminants.  PD-Byonic search parameters were as follows: fully 
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Tryptic peptides with no more than 2 missed cleavages, precursor mass tolerance of 10 ppm, fragment 
mass tolerance of 20 ppm, and a maximum of 2 common modifications and 2 rare 
modifications.  Cysteine carbamidomethylation was set as a static modification, while methionine 
oxidation was a common dynamic modification (up to 2 per peptide).  Methionine loss on protein N-
termini, methionine loss + acetylation on protein N-termini, protein N-terminal acetylation, and lysine 
acetylation were rare dynamic modifications (only 1 each).  Byonic protein-level FDR was set at 0.01, 
while Percolator FDRs were set at 0.01 (strict) and 0.05 (relaxed).  In the consensus step, peptide and 
PSM FDRs were set at 0.001 (strict) and 0.01 (relaxed), with peptide confidence at least medium, lower 
confidence peptides excluded, minimum peptide length set at 6, and apply strict parsimony set to 
false.  Quantified peptides included unique + razor, protein groups were considered for peptide 
uniqueness, shared Quan results were not used, and Quan results with missing values were not 
rejected.  Precursor abundances were determined based on intensity, and the protein abundances 
were calculated as the sum of each protein's peptide group abundances.  The protein abundances were 
then used to estimate purity of the GNS prep, with the GNS abundance set at 100% and all other 
proteins normalized to this.
